Corporate Profile

CinCor is a clinical-stage biopharmaceutical company with a mission to dramatically improve the treatment paradigm for patients suffering from hypertension and other cardio-renal diseases. Its lead asset, baxdrostat (CIN-107), is a first-in-class, highly selective oral small molecule aldosterone synthase inhibitor, which is in clinical development for hypertension and other cardio-renal diseases.

News Releases
News Release
CinCor Reports First Quarter Financial Results and Provides Corporate Update
Topline data for baxdrostat (CIN-107) in BrigHtn Phase 2 trial for treatment-resistant hypertension (rHTN) expected in 2H 2022 Topline data for baxdrostat (CIN-107) in HALO Phase 2 trial for uncontrolled hypertension (uHTN) expected in 2H 2022 Phase 2 figHTN-CKD trial evaluating baxdrostat’s
News Release
CinCor Pharma to Participate in Jefferies Biotech on the Bay Summit
WALTHAM, Mass., April 19, 2022 (GLOBE NEWSWIRE) --  CinCor Pharma, Inc. (“CinCor”) today announced its participation in the Jefferies Biotech on the Bay Summit taking place April 26-27 in Miami, Florida. The CinCor management team will participate in one-on-one investor meetings during the event.
Events
Latest Presentation
CinCor Pharma Corporate Presentation – May 2022